Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PIP4K2A | P48426 | 3/20 | 0.33 |
| ▸ | PIP4K2B | P78356 | 3/20 | 0.33 |
| ▸ | F10 | P00742 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.30 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.30 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2111629 | 1.00 | CYP3A4 (0.41) | CYP3A4PIP4K2APIP4K2BF10ALDH1A1 | |
| SCHEMBL2112174 | 0.81 | CYP3A4 (0.59) | CYP3A4F10ALDH1A1LMNAGSK3B | |
| SCHEMBL2112172 | 0.81 | CYP3A4 (0.59) | CYP3A4F10ALDH1A1LMNAGSK3B | |
| SCHEMBL1542176 | 0.77 | CYP3A4 (0.68) | CYP3A4PIP4K2APIP4K2BPIP4K2C | |
| SCHEMBL2128628 | 0.77 | CYP3A4 (0.68) | CYP3A4PIP4K2APIP4K2BPIP4K2C | |
| SCHEMBL2520555 | 0.75 | CYP3A4 (0.51) | CYP3A4PIP4K2APIP4K2BALDH1A1LMNA | |
| SCHEMBL2520553 | 0.75 | CYP3A4 (0.51) | CYP3A4PIP4K2APIP4K2BALDH1A1LMNA | |
| SCHEMBL2111179 | 0.75 | CYP3A4 (0.39) | CYP3A4PIP4K2APIP4K2BF10GSK3B | |
| SCHEMBL2111175 | 0.75 | CYP3A4 (0.39) | CYP3A4PIP4K2APIP4K2BF10GSK3B | |
| SCHEMBL1542956 | 0.74 | CYP3A4 (0.52) | CYP3A4PIP4K2APIP4K2BPIP4K2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158631-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100330032-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | CHIN ELBERT | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330032-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, HCCS, RTF2 | CYP3A4 305/4885PIP4K2A 2093/4885PIP4K2B 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.